SURAKSHASuraksha Diagnostic Ltd.
Suraksha Diagnostic Q2 FY27 Results: Consolidated Net Profit ₹14.95 Crore on Total Income of ₹101 Crore
- Earnings
- diagnostics

Suraksha Diagnostic (NSE: SURAKSHA) reported consolidated total income of ₹100.58 crore and net profit of ₹14.95 crore for the quarter ended 30 Sep 2026, and standalone total income of ₹96.50 crore and net profit of ₹15.30 crore, it said in a filing on 10 Nov 2026.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹100.58 crore, up 26.4% YoY and 13.3% QoQ
- Net profit: ₹14.95 crore, up 69.4% YoY and 16.4% QoQ
- EPS: ₹2.88 basic, against ₹1.73 a year earlier
- Finance costs: ₹4.84 crore, up 74.3% YoY
Standalone
The company on its own, without its subsidiaries
- Total income: ₹96.50 crore, up 25.0% YoY and 12.7% QoQ
- Net profit: ₹15.30 crore, up 63.4% YoY and 21.6% QoQ
- EPS: ₹2.93 basic, against ₹1.80 a year earlier
- Finance costs: ₹4.79 crore, up 76.1% YoY
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 100.58 | 79.58 | +26.4% | 88.73 | +13.3% | |
| Revenue from operations | 99.07 | 78.73 | +25.8% | 87.65 | +13.0% |
| Other income | 1.50 | 0.85 | +76.7% | 1.09 | +38.3% |
| 14.95 | 8.83 | +69.4% | 12.85 | +16.4% | |
| Profit before tax | 18.87 | 12.05 | +56.7% | 16.53 | +14.2% |
| Finance costs | 4.84 | 2.78 | +74.3% | 3.72 | +30.0% |
| Depreciation | 12.61 | 10.14 | +24.3% | 11.28 | +11.7% |
| Tax expense | 3.92 | 3.22 | +21.8% | 3.68 | +6.6% |
| Net profit margin | 14.86% | 11.09% | +3.77 pp | 14.48% | +0.39 pp |
| EPS, basic (₹) | 2.88 | 1.73 | +66.5% | 2.50 | +15.2% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit grew faster than income. Consolidated net profit rose 69.4% YoY against a 26.4% rise in total income, and profit before tax rose 56.7%.
Other income of ₹1.50 crore is 1.5% of total income this quarter, and 8.0% of profit before tax of ₹18.87 crore. Finance costs of ₹4.84 crore are 4.8% of total income, up from ₹2.78 crore a year earlier. Depreciation rose 24.3% to ₹12.61 crore.
The auditor did not review interim results of six subsidiaries, which reflect total revenues of ₹5.26 crore for the quarter before consolidation adjustments. The auditor, MSKA & Associates LLP, issued an unmodified limited review conclusion on the consolidated results.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 96.50 | 77.23 | +25.0% | 85.65 | +12.7% | |
| Revenue from operations | 94.53 | 76.26 | +24.0% | 84.09 | +12.4% |
| Other income | 1.97 | 0.97 | +103.7% | 1.56 | +25.9% |
| 15.30 | 9.36 | +63.4% | 12.58 | +21.6% | |
| Profit before tax | 19.18 | 12.57 | +52.6% | 16.21 | +18.3% |
| Finance costs | 4.79 | 2.72 | +76.1% | 3.67 | +30.4% |
| Depreciation | 11.88 | 9.65 | +23.1% | 10.60 | +12.1% |
| Tax expense | 3.88 | 3.21 | +21.1% | 3.63 | +6.9% |
| Net profit margin | 15.85% | 12.12% | +3.73 pp | 14.69% | +1.16 pp |
| EPS, basic (₹) | 2.93 | 1.80 | +62.8% | 2.42 | +21.1% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 63.4% YoY, from ₹9.36 crore to ₹15.30 crore, against a 25.0% rise in total income. Profit before tax rose 52.6%, and tax expense of ₹3.88 crore is 20.2% of profit before tax of ₹19.18 crore.
Other income of ₹1.97 crore rose 103.7% YoY and is 10.3% of profit before tax. Finance costs of ₹4.79 crore are 5.0% of total income, against ₹2.72 crore a year earlier, and depreciation rose 23.1% to ₹11.88 crore.
Standalone net profit of ₹15.30 crore is ₹0.35 crore above consolidated net profit of ₹14.95 crore for the quarter. Consolidated total income is ₹4.08 crore higher than standalone.
The company says it is primarily engaged in diagnostic centres for pathology and radiology services and has no separate reportable segments. The consolidated results include six entities, among them Suraksha Radiology Private Limited and Fetomat Wellness Private Limited.
Consolidated net profit attributable to owners was ₹15.01 crore for the quarter, and ₹28.02 crore for the six months against ₹18.38 crore a year earlier. Quarterly figures are compared with the year-earlier quarter and the quarter before.
Inference
The filing reports the results and an unmodified limited review conclusion, and it does not state a dividend or a record date. A reader would want to know whether a dividend is planned, and the filing does not say.
The filing does not state the reasons for the rise in depreciation or in finance costs against the year-earlier quarter.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

